Prot# CAMN107G2301: A Randomized, Open-Label, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib versus Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/25/08 → 12/30/17

Funding

  • Novartis Pharmaceuticals Corporation (CAMN107G2301)